Preclinical efficacy of THRX-200495, a dual pharmacology muscarinic receptor antagonist and β(2)-adrenoceptor agonist (MABA).

[1]  T. Steinfeld,et al.  Multivalent dual pharmacology muscarinic antagonist and β₂ agonist (MABA) molecules for the treatment of COPD. , 2012, Progress in medicinal chemistry.

[2]  L. Jones,et al.  Dual-pharmacology muscarinic antagonist and β₂ agonist molecules for the treatment of chronic obstructive pulmonary disease. , 2011, Future medicinal chemistry.

[3]  A. Swensen,et al.  Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. , 2011, Respiratory medicine.

[4]  M. Mammen,et al.  THRX-198321 Is a Bifunctional Muscarinic Receptor Antagonist and β2-Adrenoceptor Agonist (MABA) That Binds in a Bimodal and Multivalent Manner , 2011, Molecular Pharmacology.

[5]  D. Tashkin,et al.  Combined treatment with formoterol and tiotropium is more efficacious than treatment with tiotropium alone in patients with chronic obstructive pulmonary disease, regardless of smoking status, inhaled corticosteroid use, baseline severity, or gender. , 2011, Pulmonary pharmacology & therapeutics.

[6]  W. Martin,et al.  Application of the classical Einthoven model of bronchoconstriction to the study of inhaled bronchodilators in rodents. , 2011, Journal of pharmacological and toxicological methods.

[7]  J. V. van Noord,et al.  QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease , 2010, Thorax.

[8]  M. Mammen,et al.  Dual-pharmacology bronchodilators for the treatment of COPD , 2010 .

[9]  J. V. van Noord,et al.  Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms. , 2010, Respiratory medicine.

[10]  T. Welte,et al.  Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. , 2009, American journal of respiratory and critical care medicine.

[11]  P. Gold,et al.  The 2007 GOLD Guidelines: a comprehensive care framework. , 2009, Respiratory care.

[12]  T. Kanazawa.  Functional Crosstalk Between β2-adrenoreceptor and Muscarinic Acetylcholine Receptor: Implications for Gene-Gene Interactions and Bronchodilatory Responses in Patients with Asthma and COPD , 2008 .

[13]  C. Vogelmeier,et al.  Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. , 2008, Respiratory medicine.

[14]  M. Littner,et al.  Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. , 2008, Respiratory medicine.

[15]  G. Rossoni,et al.  Positive interaction of the novel beta2-agonist carmoterol and tiotropium bromide in the control of airway changes induced by different challenges in guinea-pigs. , 2007, Pulmonary pharmacology & therapeutics.

[16]  S. Liggett,et al.  Crosstalk between Gi and Gq/Gs pathways in airway smooth muscle regulates bronchial contractility and relaxation. , 2007, The Journal of clinical investigation.

[17]  J. Bourbeau,et al.  Tiotropium in Combination with Placebo, Salmeterol, or FluticasoneSalmeterol for Treatment of Chronic Obstructive Pulmonary Disease , 2007, Annals of Internal Medicine.

[18]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[19]  G. Villetti,et al.  Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea‐pig and human airways , 2006, British journal of pharmacology.

[20]  J. V. van Noord,et al.  Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. , 2006, Chest.

[21]  A. Fryer,et al.  Beta2-agonist and anticholinergic drugs in the treatment of lung disease. , 2005, Proceedings of the American Thoracic Society.

[22]  J. Donohue,et al.  Role of bronchodilators in chronic obstructive pulmonary disease. , 2005, Seminars in respiratory and critical care medicine.

[23]  M. Cazzola,et al.  The functional impact of adding salmeterol and tiotropium in patients with stable COPD. , 2004, Respiratory medicine.

[24]  V. Lagente,et al.  A Nitric Oxide-Releasing Salbutamol Elicits Potent Relaxant and Anti-Inflammatory Activities , 2004, Journal of Pharmacology and Experimental Therapeutics.

[25]  R. Dahl,et al.  Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study , 2002, European Respiratory Journal.

[26]  D. Rogers.  Motor control of airway goblet cells and glands. , 2001, Respiration physiology.

[27]  A. Young,et al.  Duration of action of inhaled vs. Intravenous beta(2)-adrenoceptor agonists in an anaesthetized guinea-pig model. , 2000, Pulmonary pharmacology & therapeutics.

[28]  A. Tobin,et al.  Cross talk between m3-muscarinic and beta(2)-adrenergic receptors at the level of receptor phosphorylation and desensitization. , 1999, Molecular pharmacology.

[29]  P. Dorinsky,et al.  The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. , 1999, Chest.

[30]  J. Wilson,et al.  Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. , 1999, Chest.

[31]  N. Gross,et al.  Inhalation by Nebulization of Albuterol-Ipratropium Combination (Dey Combination) Is Superior to Either Agent Alone in the Treatment of Chronic Obstructive Pulmonary Disease , 1998, Respiration.

[32]  M. Takeuchi,et al.  Selective muscarinic antagonists. II. Synthesis and antimuscarinic properties of biphenylylcarbamate derivatives. , 1998, Chemical & pharmaceutical bulletin.

[33]  K. Kubo,et al.  Acetylcholine stimulates alveolar macrophages to release inflammatory cell chemotactic activity. , 1998, The American journal of physiology.

[34]  B. J. Knoll,et al.  Salmeterol‐induced desensitization, internalization and phosphorylation of the human β2‐adrenoceptor , 1998, British journal of pharmacology.

[35]  G. Oberdörster,et al.  Intratracheal inhalation vs intratracheal instillation: differences in particle effects. , 1997, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[36]  K. Dobashi,et al.  Induction of muscarinic receptor subtypes in monocytic/macrophagic cells differentiated from EoL-1 cells. , 1996, European journal of pharmacology.

[37]  P. Barnes,et al.  Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. , 1995, Life sciences.

[38]  S. Spiro,et al.  Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution. , 1990, Thorax.

[39]  K. Standifer,et al.  Carbostyril derivatives having potent beta-adrenergic agonist properties. , 1987, Journal of medicinal chemistry.

[40]  A. Fryer,et al.  Ipratropium bromide potentiates bronchoconstriction induced by vagal nerve stimulation in the guinea-pig. , 1987, European journal of pharmacology.

[41]  Kazuyuki Nakagawa,et al.  SYMPATHOMIMETIC AMINES HAVING A CARBOSTYRIL NUCLEUS , 1977 .

[42]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.